AstraZeneca Tops Q3 Forecasts, Holds Full‑Year Guidance Amid Cost and Patent Headwinds

Post by : Bianca Suleiman

AstraZeneca exceeded analysts' expectations in the third quarter thanks to strong demand for its cancer and cardiovascular drugs, yet the company chose not to revise its full‑year forecast, leaving some investors wanting clearer guidance.

On a constant currency basis, revenue for the three months ended Sept. 30 was $15.19 billion, up 10% year‑on‑year and ahead of the $14.79 billion consensus. Core earnings per share climbed 12% to $2.38, topping forecasts of $2.29.

The Anglo‑Swedish group said blockbuster oncology and heart medicines underpinned the performance, while management warned of impending patent expiries — including for diabetes and cardiovascular product Farxiga — that it aims to counter with forthcoming launches such as a new blood‑pressure treatment. U.S. sales, the company’s largest market, rose 9% to $6.55 billion, while China delivered $1.76 billion, a 5% increase despite tighter regulatory scrutiny.

Despite the upbeat quarterly figures, AstraZeneca maintained its full‑year guidance: high single‑digit revenue growth and a low double‑digit rise in core earnings. Executives cited rising costs and intensifying generic competition as reasons for caution; core operating expenses increased 9% to $21.6 billion over the first nine months.

The group is pursuing a new U.S. drug‑pricing agreement and has signalled plans to list on the New York Stock Exchange to strengthen its capital position. Management said any impact from the pricing deal is expected to be manageable.

Overall, the results illustrate AstraZeneca’s ability to generate robust sales while also reflecting the strategic challenges of navigating patent cliffs, cost pressures and regulatory complexity across key markets.